BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LT-002-158 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LT-002-158\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07895615-1416@assetmemo.bio
DTSTAMP:20261121T005454Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:LT-002-158: Phase 2 readout est. (NCT07895615)
DESCRIPTION:LT-002-158\, phase 2\, Atopic Dermatitis.\nStudy: Phase II Clin
 ical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Ad
 ult Patients With Moderate-to-Severe Atopic Dermatitis\nEstimated primary 
 completion: January 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lt-002-158#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07895615
URL:https://assetmemo.bio/drug/lt-002-158#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931990-1416@assetmemo.bio
DTSTAMP:20261121T005454Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:LT-002-158: Phase 1/2 readout est. (NCT06931990)
DESCRIPTION:LT-002-158\, phase 1/2\, Atopic Dermatitis.\nStudy: A Study to 
 Explore the Safety\, Tolerability\, Efficacy\, and Pharmacokinetics of LT-
 002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis\nEstimate
 d primary completion: 17 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lt-002-158#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06931990
URL:https://assetmemo.bio/drug/lt-002-158#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932003-1416@assetmemo.bio
DTSTAMP:20261121T005454Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:LT-002-158: Phase 1/2 readout est. (NCT06932003)
DESCRIPTION:LT-002-158\, phase 1/2.\nStudy: A Study to Explore the Safety\,
  Tolerability\, Efficacy\, and Pharmacokinetics of LT-002-158 Tablets in C
 hinese Adult Patients With Hidradenitis Suppurativa\nEstimated primary com
 pletion: 30 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/lt-002-158#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06932003
URL:https://assetmemo.bio/drug/lt-002-158#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
